Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
- Predictors of Treatment with Duloxetine or Venlafaxine XR among Adult Patients Treated for Depression in Primary Care Practices in the United Kingdom. Shi, Nianwen; Durden, Emily; Torres, Amelito; Cao, Zhun; Happich, Michael // Depression Research & Treatment;2012, p1
Background. Knowledge about real-world use of duloxetine and venlafaxine XR to treat depression in the UK is limited. Aims. To identify predictors of duloxetine or venlafaxine XR initiation. Method. Adult depressed patients who initiated duloxetine or venlafaxine XR between January 1, 2006 and...
- Duloxetine and Venlafaxine Induced Akathisia: Two Case Reports. Izci, Filiz; Bozkurt Zincir, Selma; Acar, Guler; Basar Semiz, Umit // Klinik Psikofarmakoloji Bulteni;Dec2013, Vol. 23 Issue 4, p357
Akathisia is a movement disorder characterized by involuntary movements resulting in discomfort and restlessness. Drug-induced akathisia is often seen with antidopaminergic antipsychotics but sometimes can be seen with other drugs. The four subtypes of akathisia are: acute, chronic, tardive and...
- Early reduction in painful physical symptoms is associated with improvements in long-term depression outcomes in patients treated with duloxetine. // BMC Psychiatry;2011, Vol. 11 Issue 1, p150
The article presents a research which examines the relationship between change of painful physical symptoms (PPS) with long-term outcomes of depressive symptoms in patients treated with duloxetine in clinical practice. It is reported that, the researchers used non-interventional study method to...
- Duloxetine/venlafaxine. // Reactions Weekly;7/17/2010, Issue 1310, p21
The article describes the case of elevated transaminase levels in a 27-year-old man with Gilbert's syndrome while being treated with duloxetine and subsequently during venlafaxine therapy.
- Duloxetine/venlafaxine. // Reactions Weekly;7/28/2012, Issue 1412, p19
The article describes the case of a 42-year-old woman who developed vomiting secondary to duloxetine and headache due to venlafaxine.
- Duloxetine. // Reactions Weekly;03/23/2013, Issue 1445, p19
The article presents a case study of a 75-year-old woman who developed microscopic colitis while undergoing treatment with duloxetine for depression.
- Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial. Zhiyang WANG; Xiufeng XU; Qingrong TAN; Keqing LI; Cui MA; Shiping XIE; Chengge GAO; Gang WANG; Huafang LI // Shanghai Archives of Psychiatry;Aug2015, Vol. 27 Issue 4, p228
Background: This study is a pre-registration trial of generic duloxetine that was approved by the China Food and Drug Administration (approval number: 2006L01603). Aim: Compare the treatment efficacy and safety of generic duloxetine to that of paroxetine in patients with major depressive...
- Comparison of the effectiveness of duloxetine in depressed patients with and without a family history of affective disorders in first-degree relatives. Shiliang WANG; Mincai QIAN; Hua ZHONG; Guohua SONG; Meijuan LU; Rui FENG; Lei ZHANG; Jianliang NI; Wei CHEN // Shanghai Archives of Psychiatry;Aug2015, Vol. 27 Issue 4, p237
Background: It remains unclear whether or not a positive family history of affective disorders predicts the effectiveness of antidepressant treatment of depression. Aim: Assess the relationship of a family history of affective disorders to the efficacy of duloxetine in the treatment of...
- Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder. Kei Nagao; Taro Kishi; Masatsugu Moriwaki; Kiyoshi Fujita; Shigeki Hirano; Yoshio Yamanouchi; Toshihiko Funahashi; Nakao Iwata // Neuropsychiatric Disease & Treatment;2013, Vol. 9, p781
No studies have compared mirtazapine with duloxetine in patients with major depressive disorder (MDD). Fifty-six patients were nonrandomly assigned to a 4-week treatment with either 15 to 45 mg/day of mirtazapine (n = 22) or 20 to 60 mg/day of duloxetine (n = 34). The primary efficacy...